Observational analysis links glucosamine use to 25% higher progression from MCI to dementia in University of Florida records

Researchers applied AI screening to University of Florida electronic health records and identified that 8% of individuals with cognitive decline reported glucosamine use. Those users showed 25% higher likelihood of advancing to dementia and 25% elevated mortality risk compared with non-users. The analysis is observational and cannot establish causality, leaving room for confounding by indication such as chronic joint disease or unmeasured lifestyle factors.

Glucosamine, an amino sugar that crosses the blood-brain barrier, was shown in genetically modified mice to increase protein O-GlcNAcylation, a modification already elevated in human Alzheimer brain tissue from the UF tissue bank. Suppressing this pathway improved memory performance in the animal model. This mechanistic thread connects to prior work on metabolic dysregulation in neurodegeneration but had not previously been tied to an over-the-counter supplement.

Existing regulatory frameworks treat glucosamine as a dietary supplement with minimal pre-market safety requirements, a pattern seen in earlier signals from vitamin E and beta-carotene trials that later revealed net harm. No large prospective cohort with repeated cognitive assessments and verified exposure has yet examined this association.

Next steps require replication in independent longitudinal datasets with pharmacy linkage and ideally an RCT restricted to MCI patients to quantify absolute risk change over three to five years.